Roivant Sciences (ROIV) Gains from Sales and Divestitures: 2022-2025
Historic Gains from Sales and Divestitures for Roivant Sciences (ROIV) over the last 2 years, with Jun 2025 value amounting to $297,795.
- Roivant Sciences' Gains from Sales and Divestitures fell 86.62% to $297,795 in Q2 2025 from the same period last year, while for Jun 2025 it was $297,795, marking a year-over-year decrease of 86.62%. This contributed to the annual value of $6.1 million for FY2025, which is 11.03% down from last year.
- Roivant Sciences' Gains from Sales and Divestitures amounted to $297,795 in Q2 2025, which was down 95.11% from $6.1 million recorded in Q1 2025.
- Over the past 5 years, Roivant Sciences' Gains from Sales and Divestitures peaked at $12.0 million during Q1 2023, and registered a low of $297,795 during Q2 2025.
- Moreover, its 3-year median value for Gains from Sales and Divestitures was $4.5 million (2023), whereas its average is $4.8 million.
- As far as peak fluctuations go, Roivant Sciences' Gains from Sales and Divestitures grew by 3.68% in 2023, and later plummeted by 86.62% in 2025.
- Roivant Sciences' Gains from Sales and Divestitures (Quarterly) stood at $5.8 million in 2022, then declined by 4.56% to $5.5 million in 2023, then decreased by 10.21% to $4.9 million in 2024, then crashed by 86.62% to $297,795 in 2025.
- Its Gains from Sales and Divestitures was $297,795 in Q2 2025, compared to $6.1 million in Q1 2025 and $4.9 million in Q4 2024.